GlaxoSmithKline (GSK) Given a GBX 1,600 Price Target by UBS Analysts

GlaxoSmithKline (LON:GSK) received a GBX 1,600 ($22.46) price target from research analysts at UBS in a research report issued on Thursday. The brokerage presently has a “buy” rating on the stock. UBS’s target price would indicate a potential upside of 12.47% from the company’s current price.

A number of other equities research analysts also recently weighed in on the company. Credit Suisse Group raised their target price on GlaxoSmithKline from GBX 1,300 ($18.25) to GBX 1,450 ($20.35) and gave the company a “neutral” rating in a report on Tuesday. Morgan Stanley set a GBX 1,400 ($19.65) price objective on GlaxoSmithKline and gave the company a “neutral” rating in a report on Tuesday. Kepler Capital Markets raised their price objective on GlaxoSmithKline from GBX 1,360 ($19.09) to GBX 1,400 ($19.65) and gave the company a “hold” rating in a report on Wednesday, March 28th. Berenberg Bank raised their price objective on GlaxoSmithKline from GBX 1,705 ($23.93) to GBX 1,780 ($24.99) and gave the company a “buy” rating in a report on Wednesday, March 28th. Finally, HSBC reissued a “buy” rating and set a GBX 2,030 ($28.50) price objective on shares of GlaxoSmithKline in a report on Wednesday, March 28th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and nine have issued a buy rating to the stock. GlaxoSmithKline currently has an average rating of “Hold” and an average target price of GBX 1,548.64 ($21.74).

How to Become a New Pot Stock Millionaire

Shares of GSK stock opened at GBX 1,422.60 ($19.97) on Thursday. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($17.34) and a fifty-two week high of GBX 1,724.50 ($24.21).

In other GlaxoSmithKline news, insider Sir Roy Anderson acquired 562 shares of the stock in a transaction dated Wednesday, February 7th. The stock was purchased at an average cost of GBX 1,278 ($17.94) per share, with a total value of £7,182.36 ($10,081.92). Also, insider Victoria Whyte sold 5,199 shares of GlaxoSmithKline stock in a transaction dated Monday, February 12th. The stock was sold at an average price of GBX 1,295 ($18.18), for a total value of £67,327.05 ($94,507.37). Over the last ninety days, insiders have acquired 591 shares of company stock worth $756,678 and have sold 23,765 shares worth $31,152,709.

WARNING: This report was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3337211/glaxosmithkline-gsk-given-a-gbx-1600-price-target-by-ubs-analysts.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

300 Token  Price Reaches $720.58 on Exchanges
300 Token Price Reaches $720.58 on Exchanges
Monaco  Price Up 70.5% Over Last Week
Monaco Price Up 70.5% Over Last Week
Lionsgate  & Genius Brands  Financial Survey
Lionsgate & Genius Brands Financial Survey
Head-To-Head Comparison: Danielson  & MGE Energy
Head-To-Head Comparison: Danielson & MGE Energy
NuVasive, Inc.  Receives $66.80 Consensus Target Price from Brokerages
NuVasive, Inc. Receives $66.80 Consensus Target Price from Brokerages
PCM  vs. Its Competitors Critical Review
PCM vs. Its Competitors Critical Review


© 2006-2018 Ticker Report. Google+.